In retrospectively conducted observational studies, the use of rivaroxaban in newly diagnosed patients with AF was associated with less progression of valvular calcification, but also with a decrease in inflammatory markers (C-reactive protein (CRP), IL-2, IL-4, TNF-α) and fibrinolytic markers (D-dimer) [138,139,140]. The gene discussed is CRP; the disease is calcification.